Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient

Clin Exp Rheumatol. 2002 Jul-Aug;20(4 Suppl 26):S43-4.


Colchicine is the treatment of choice in familial Mediterranean fever (FMF) both for attacks and for prevention of secondary amyloidosis. The overall non-responder rate varies from 5-10 to 40%. Thalidomide is known to blunt the acute phase response. We report the efficacy of the addition of thalidomide to colchicine in controlling the febrile attacks and acute phase response in a patient with FMF resistant to 2 mg colchicine per day.

Publication types

  • Case Reports

MeSH terms

  • Colchicine / therapeutic use*
  • Drug Therapy, Combination
  • Familial Mediterranean Fever / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Thalidomide / therapeutic use*


  • Immunosuppressive Agents
  • Thalidomide
  • Colchicine